Document is current
Any future updates will be listed below
-
Authors
Cillo, Anthony R.
Kirkwood, John M. https://orcid.org/0000-0002-3570-4476
- License Information
-
More Information
Article History
First Online: 5 August 2025
Competing interests
: J.M.K. has received consulting fees from Ankyra Therapeutics, Axio Research, Boxer Capital, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, DermTech, Engage Health Media, IQVIA, Istari Oncology, Lumira Capital Investment Management, Lytix Biopharma, Merck, Mural Oncology, Natera, Novartis, OncoCyte, PathAI, Pfizer, Piper Sandler, Regeneron Pharmaceuticals, Replimune, Scopus BioPharma, Takeda, Valar Labs, and Zola Therapeutics; and research funding (to his institution) from Bristol Myers Squibb, Checkmate Pharmaceuticals, Harbour BioMed, Immvira Pharma, Immunocore, Iovance Biotherapeutics, Lion Biotechnologies, Lytix Biopharma, Novartis, Takeda, and Verastem. A.R.C. declares no competing interests.
